MedTrace Logo

Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment

NCT05347082 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2022-05-06

No results posted yet for this study

Summary

Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world. Chronic exposure to the parathyroid hormone (PTH) is catabolic for the bone, worsening the state of osteoporosis. However, it is unclear whether these conditions could significantly improve bone mineral density (BMD). In the present work, it was shown that the resolution of hyperparathyroidism in postmenopausal women improves osteoporosis.

Conditions

  • Postmenopausal Osteoporosis
  • Postmenopause
  • Hyperparathyroidism, Secondary
  • Hypovitaminosis D
  • Hyperparathyroidism, Primary

Interventions

DRUG

Cholecalciferol

Tablets of 4000 IU

Sponsors & Collaborators

  • Universidad Nacional Autonoma de Mexico

    collaborator OTHER

  • National Polytechnic Institute, Mexico

    collaborator OTHER

  • Hospital Regional 1o de Octubre

    lead OTHER

Principal Investigators

  • Juan M Ocampo Godínez, M.D., Ph.D. · Tissue Bioengineering Laboratory, National Autonomous University of Mexico [UNAM]

  • Patricia Loranca-Moreno, M.D., M.Sc. · Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE.

  • Paula M Sánchez-Tinoco, M.D. · Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2021-12-29
Completion
2022-02-20

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05347082 on ClinicalTrials.gov